



AETNA BETTER HEALTH®  
Coverage Policy/Guideline

Name: Evenity

Page: 1 of 2

Effective Date: 6/1/2026

Last Review Date: 4/2/2026

Applies to:  Illinois

### Intent:

The intent of this policy/guideline is to provide information to the prescribing practitioner outlining the coverage criteria for Evenity under the patient's prescription drug benefit.

### Description:

#### FDA-Approved Indication

Evenity is indicated for the treatment of osteoporosis in postmenopausal women at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy.

Limitations of Use: Limit duration of use to 12 monthly doses. If osteoporosis therapy remains warranted, continued therapy with an anti-resorptive agent should be considered.

All other indications are considered experimental/investigational and not medically necessary.

### Drug List:

Evenity

### Policy/Guideline:

#### Documentation

Submission of the following information is necessary to initiate the prior authorization review:

- Chart notes or medical record documentation indicating a history of fragility fractures, T-score, and Fracture Risk Assessment Tool (FRAX) fracture probability as applicable to the coverage criteria section.
- Chart notes, medical record documentation, or claims history supporting previous medications tried (if applicable), including response to therapy.

#### Postmenopausal osteoporosis treatment

Authorization of a total of 12 months may be granted to postmenopausal members with osteoporosis when EITHER of the following criteria is met:

- Member has a history of fragility fractures (e.g., low trauma fracture from force similar to a fall from standing position).
- Member has a pre-treatment T-score  $\leq -2.5$  OR member has osteopenia (i.e., pre-treatment T-score between -1 and -2.5) with a high pre-treatment FRAX probability (see Appendix) and meets ANY of the following criteria:
  - Member has indicators of very high fracture risk (e.g., advanced age, frailty, glucocorticoid use, very low T-scores [ $\leq -3$ ], or increased fall risk)
  - Member has had an inadequate response or intolerance to previous injectable osteoporosis therapy



AETNA BETTER HEALTH®  
Coverage Policy/Guideline

Name:	Evenity	Page:	2 of 2
Effective Date:	6/1/2026	Last Review Date:	4/2/2026
Applies to:	<input checked="" type="checkbox"/> Illinois		

- Member has had an inadequate response or intolerance to previous oral bisphosphonate therapy

### Continuation of Therapy

All members (including new members) requesting authorization for continuation of therapy must meet all requirements in the coverage criteria section and have received less than 12 monthly doses of Evenity.

### Approval Duration and Quantity Restrictions:

**Approval:** Initial and Renewal: 12 months

**Quantity Level Limit:** Reference Formulary for drug specific quantity level limits

### Appendix

FRAX Fracture Risk Assessment Tool

- FRAX® (fracture risk assessment tool) available at: <https://fraxplus.org>
- High FRAX probability: 10-year major osteoporotic fracture probability  $\geq 20\%$  or hip fracture probability  $\geq 3\%$
- FRAX Glucocorticoid correction: If glucocorticoid dose is greater than 7.5 mg (prednisone equivalent) per day, the estimated risk score generated with FRAX should be multiplied by 1.15 for major osteoporotic fracture (including fractures of the spine [clinical], hip, wrist, or humerus) and 1.2 for hip fracture.

### References:

1. Evenity [package insert]. Thousand Oaks, CA: Amgen; April 2025.
2. LeBoff MS, Greenspan SL, Insogna KL, et al. The Clinician's guide to prevention and treatment of osteoporosis. *Osteoporos Int.* 2022;33(10): 2049-2102.
3. Camacho PM, Petak SM, Binkley N, et al. American Association of Clinical Endocrinologists/American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis-2020 update. *Endocr Pract.* 2020;26 (Suppl 1):1-46.
4. Eastell R, Rosen CJ, Black DM, et al. Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Clinical Practice Guideline. *J Clin Endocrinol Metab.* 2019;104:1595-1622.
5. Shoback D, Rosen CJ, Black DM, et al. Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Clinical Practice Guideline. *J Clin Endocrinol Metab.* 2020;105(3):587-594.
6. Carey, John. What is failure of bisphosphonate therapy for osteoporosis. *Cleve Clinic J Med.* 2005; 72:1033-1039.
7. FRAX® Fracture Risk Assessment Tool. © Osteoporosis Research Ltd, UK. Available online: <https://fraxplus.org>. Accessed September 5, 2025.
8. Ensrud KE, Crandall CJ. Osteoporosis. *Ann Intern Med.* 2024;177(1):ITC1-ITC16.